Sumitomo Mitsui Trust Holdings Inc. Decreases Stock Holdings in Catalent, Inc. (NYSE:CTLT)

Sumitomo Mitsui Trust Holdings Inc. reduced its stake in shares of Catalent, Inc. (NYSE:CTLT) by 1.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 433,594 shares of the company’s stock after selling 7,318 shares during the quarter. Sumitomo Mitsui Trust Holdings Inc. owned approximately 0.24% of Catalent worth $19,481,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in CTLT. CWM LLC lifted its stake in shares of Catalent by 19.7% during the 3rd quarter. CWM LLC now owns 6,113 shares of the company’s stock worth $278,000 after purchasing an additional 1,005 shares during the last quarter. Kentucky Retirement Systems purchased a new stake in shares of Catalent during the 3rd quarter worth $664,000. Kentucky Retirement Systems Insurance Trust Fund purchased a new stake in shares of Catalent during the 3rd quarter worth $296,000. Park Place Capital Corp raised its stake in Catalent by 25.2% in the third quarter. Park Place Capital Corp now owns 1,533 shares of the company’s stock valued at $70,000 after buying an additional 309 shares during the last quarter. Finally, Exchange Traded Concepts LLC purchased a new stake in Catalent in the third quarter valued at about $31,000.

Catalent Stock Up 1.0 %

Catalent stock opened at $56.05 on Tuesday. The firm has a market cap of $10.14 billion, a price-to-earnings ratio of -8.24, a price-to-earnings-growth ratio of 5.98 and a beta of 1.20. Catalent, Inc. has a 52 week low of $31.45 and a 52 week high of $60.20. The business’s 50-day moving average price is $56.81 and its 200 day moving average price is $48.30. The company has a quick ratio of 1.73, a current ratio of 2.48 and a debt-to-equity ratio of 1.34.

Catalent (NYSE:CTLT) last posted its earnings results on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.22). The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.01 billion. Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The firm’s revenue was down 10.2% on a year-over-year basis. During the same period last year, the business earned $0.62 earnings per share. As a group, sell-side analysts anticipate that Catalent, Inc. will post 0.28 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on CTLT shares. UBS Group reiterated a “neutral” rating and issued a $63.50 price target (up from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a research note on Tuesday, February 20th. StockNews.com assumed coverage on Catalent in a research note on Friday. They issued a “sell” rating for the company. Stephens reissued an “equal weight” rating and issued a $63.50 price objective on shares of Catalent in a report on Thursday, April 4th. Finally, Barclays increased their price objective on Catalent from $45.00 to $47.00 and gave the company an “equal weight” rating in a report on Thursday, January 25th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $52.46.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.